

## Curriculum Vitae Keyur Parikh, MD

Great Lakes Gastroenterology, LLC  
Great Lakes Gastroenterology Research, LLC  
Great Lakes Medical Research, LLC  
8877 Mentor Avenue  
Mentor, OH 44060

The Endoscopy Center of Lake County  
9614 Old Johnnycake Ridge Road  
Mentor, OH 44060  
440-205-1225  
[keyur023@gmail.com](mailto:keyur023@gmail.com)

### Board Certifications

2014 American Board of Internal Medicine – Internal Medicine  
2017 American Board of Internal Medicine - Gastroenterology

### Education

2014-2017 Fellowship, Gastroenterology and Hepatology  
Case Western Reserve University School of Medicine  
University Hospitals, Cleveland, OH  
2012-2014 Residency, Internal Medicine  
Case Western Reserve University School of Medicine  
University Hospitals, Cleveland, OH  
2011-2012 Internship, Internal Medicine  
University of Southern California, Los Angeles, CA  
2007-2011 Wayne State University School of Medicine  
2003-2007 Xavier University, Cincinnati, OH

### Hospital and Academic Appointments

2017-present Chairman of Gastroenterology  
Lake Health Medical System  
2017-Present Assistant Clinical Professor  
University Hospitals Cleveland Medical Center  
Case Western Reserve University School of Medicine  
2018- Present Assistant Clinical Professor  
Heritage College of Osteopathic Medicine

### Honors, Awards and Grants

2005 Undergraduate Research Grant, Xavier University, Cincinnati, OH  
2007 University Grant, Breuggeman International Studies Fellowship,  
Xavier University, Cincinnati, OH  
2008 Graduate Research Grant, Wayne State University School of Medicine, Detroit, MI  
2015 GI Jeopardy Competition Finalist, American College of Gastroenterology,  
National Meeting and Convention, Honolulu, HI  
2015 Lansing G Hoskins Education and Research Fund Grant, Case Western Reserve University,  
University Hospitals Case Medical Center, Cleveland, OH

### Memberships

2015- Present ASGE Bariatric Endoscopy Special Interest Group  
2014- Present American Society of Gastrointestinal Endoscopy  
2014- Present American College of Gastroenterology  
2014- Present American Gastroenterological Association  
2011- 2014 American Medical Association

## Committees

Chair, GI Services Committee  
Lake Health Systems  
Lake County, OH

Quality Committee Chair  
The Endoscopy Center  
Mentor, OH

ICU Committee  
Lake Health Systems  
Lake County, OH

Infection Control Committee  
Lake Health Systems  
Lake County, OH

Patient Satisfaction Committee  
University of Southern California, USC+LAC Medical Center  
Los Angeles, CA

Quality and Patient Safety Committee  
University Hospital Case Medical Center  
Cleveland, OH

GI Career Development Interest Group  
University Hospital Case Medical Center  
Cleveland, OH

## Research Affiliations

2017-Present Investigator  
Great Lakes Gastroenterology Research, LLC  
Great Lakes Medical Research, LLC  
8877 Mentor Avenue, Mentor, OH 44060

2017-Present Investigator  
The Endoscopy Center of Lake County  
9614 Johnnycake Ridge Road, Mentor, OH 44060

## Publications

1. **Parikh K**, Khaitan L. Radiofrequency ablation coupled with roux-en-y gastric bypass: A treatment option for morbidly obese patients with Barrett's esophagus. J Surg Case Rep. Accepted.
2. **Parikh K**, Ali MA, Wong RC. Unusual Causes of Upper GI Bleeding. Gastrointest Endosc Clin N Am. 2015 Jul; 25 (3): 583-605
3. **Parikh K**, Umbel J, Venkat D. An Unexpected Cause of Dysphagia. Clin Gastroenterol Hepatol. 2015 Feb 24. pii: S1542-3565(15)00164-0
4. Gayar OH, Robbins JR, **Parikh K**, Lu M, Buekers T, Munkarah A, Elshaik MA. Hysterectomy for uterine adenocarcinoma in the elderly: tumor characteristics, and long-term outcome. Gynecol Oneal. 2011 Oct; 123(1): 71-5

## Book Chapter

**Parikh K**, Wong RC. "Diagnostic Endoscopy During PEG ". Percutaneous Endoscopic

Gastrostomy (PEG): Techniques, Effectiveness and Potential Complications. Chapter:  
"Technique: PUSH." Pauli E & Marks J (eds). Nova Science Publishers. 2017

### Presentations

1. Sheriff M, Mansoor E, Cooper GC, **Parikh K**. Trisomy 21 Does Not Increase the Risk of Colorectal Cancer, and the Rates of Colonoscopies Do Not Significantly Differ in Patients with Trisomy 21 - A Population Based National Study In The United States. *DDW 2019*
2. Natu A, **Parikh K**, Sharma R, Nadeem F, Ali MA, Dumot J, Faulx A, Isenberg GA, Wong RCK, Chak A. Evaluation of Patient Outcomes After Endoscopic Resection of Large Polyps. *DDW 2016*
3. **Parikh K**, Bou-Abboud C, Yasinow S, Wang J, Ryder C, Chak A. Is Esophageal Sampling Necessary For Diagnosis of Esophageal Candidiasis? *DDW 2016*
4. Sharma R, **Parikh K**, Bou-Abboud C, Buch N, Post A, Isenberg GA. The Utility of Small Bowel Capsule Endoscopy (SBCE) to Determine Small Bowel Transit Time (SBTI) and its Relationship with Spontaneous Bacterial Peritonitis (SBP) and Hepatic Encephalopathy (HE) in Cirrhotics. *DDW 2016*
5. Dakhoul L, **Parikh K**, Berkelhammer C, Ho EV. Fecal microbiota transplant in treatment of Clostridium difficile colitis-pooled data analysis and a systematic review. *DDW 2017*
6. Saxena A, **Parikh K**, Lu C, Chak A, Greer KG, Cooper GS Alashkar B, Faulx AL. Late Stage Diagnosis of Esophageal Adenocarcinoma (EAC) among Veterans - Could Screening be Effective? *DDW 2014*
7. **Parikh K**. Hepatic Pseudoaneurysm Causing Massive GI Hemorrhage. Oral Presentation. October 2015. *23rd Anthony S. Tavill Citywide Liver Rounds*. Cleveland, OH.
8. **Parikh K**. A Case of Cryoglobulinemia. Oral Presentation. August 2014. *20th Anthony S. Tavill Citywide Liver Rounds*. Cleveland, OH.
9. **Parikh K**, Rogers D. Characterizing Cost Consciousness Among Interns in Inpatient General Medicine and the Effectiveness of a Brief Educational Intervention. Poster session. May 2014. *Research Day: UHCCM*. Cleveland, OH.
10. **Parikh K**, Liu S. *Diffuse Malignant Peritoneal Mesothelioma Presenting as a Scrotal Mass*. Poster session. *Resident Research Day*. July 2012. Los Angeles, CA.
11. **Parikh K**, Loutfi R. *A Unique Presentation of Dermatomyositis in Recurrent Breast Cancer*. Poster session. *Resident and Student Poster Symposium*; Jan 2010. Detroit, MI.
12. **Parikh K**. Synthesis of Lopinavir Based Derivatives for Inhibition of MOR Human HIV Protease. *Wayne State University Department of Biochemistry Annual Research Update*. Aug 2008. Detroit, MI
13. **Parikh K**, Mullins R. The role of Vinyl Thiazoline in the Biological Activity and Total Synthesis of Kalkitoxin. *Regional Undergraduate Research Symposium*. April 2007. Cincinnati, OH.

### Clinical Research Experience

#### Principal Investigator

2016-2017	L-Menthol Injection as a Novel Technique during Colonoscopy -The MINT-C Study <b>IND #128323</b> <b>Phase 3</b> <b>Investigator Led</b>
2019-Present	A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Adult and Adolescent Patients with Active Eosinophilic Esophagitis <b>AK002-014</b> <b>Phase 2/3</b> <b>Allakos, Inc.</b>
2019-Present	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Patients with Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (formerly referred to as Eosinophilic Gastroenteritis) Who Have an Inadequate Response with, Lost Response to, or Were Intolerant to Standard Therapies

2019-Present	<b>AK002-016</b> A Prospective Study to Identify the Prevalence of Eosinophilic Gastrointestinal Diseases and Elevated Tissue Mast Cells among Patients with Chronic Gastrointestinal Symptoms	<b>Phase 3</b>	<b>Allakos, Inc.</b>
2020-Present	<b>AK002-019</b> Observational Study to Establish Normal Levels of Gastrointestinal Tissue Eosinophils and Mast Cells in Healthy Volunteers		<b>Allakos, Inc.</b>
	<b>AK002-020</b>		<b>Allakos, Inc.</b>
<i>Sub-Investigator</i>			
2017-Present	A Multi-Center, Open-Label Study Of Cp-690,550 In Subjects With Moderate To Severe Ulcerative Colitis		
2017-Present	<b>A3921139</b> Phase ID, Randomized, Double-Blind, Double-Dummy, Placebo- Controlled, Multi.center Study to Evaluate the Efficacy for (Induction of Remission) and Safety of Etrolizumab Compared with Placebo in Patients with Moderate to Severe Ulcerative Colitis Who are Naive to TNF Inhibitors	<b>Phase 3</b>	<b>Pfizer</b>
2017-Present	<b>GA28949</b> Phase III, Double Blind, Placebo Controlled, MultCenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients with Moderate to Severe Active Ulcerative Colitis Who are Refractory of TNF Inhibitors	<b>Phase 3</b>	<b>Genentech</b>
2017-Present	<b>GA28950</b> An Open-Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase III Studies	<b>Phase 3</b>	<b>Genentech</b>
2017- 2018	<b>GA28951</b> Clinical Study of the fCAL ELISA as an aid in the differentiation between IBD from IBS	<b>Phase 3</b>	<b>Genentech</b>
2017- Present	<b>ALPCal-01</b> Phase III, Randomized, Double-Blind, Placebo-Controlled, MultiCenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction and Maintenance Treatment for Patients with Moderately to Severely Active Crohn's Disease.		<b>Buhlmann</b>
2017- Present	<b>GA29144</b> An Open-Label Extension and Safety Monitoring Study of Patients with Moderately to Severely Active Crohn's Disease Previously Enrolled in The Etrolizumab Phase III Protocol GA29144.	<b>Phase 3</b>	<b>Genentech</b>
2017- Present	<b>GA29145</b> Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) with Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study	<b>Phase 3</b>	<b>Genentech</b>
2017-2018	<b>SHP621-301/302</b> Bl 695501 versus Humira in patients with active Crohn's disease: a randomized, double-blind, multicenter, parallel group, non-inferiority trial comparing efficacy, endoscopic improvement, safety, and immunogenicity.	<b>Phase 3</b>	<b>Shire</b>
2017-2018	<b>BI695501</b> A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Sprinkle Formulation of Lubiprostone, in Adult Subjects with Chronic Idiopathic Constipation	<b>Phase 3</b>	<b>Boehringer Ingelheim</b>
2017-Present	<b>SCMP-0211-302</b> Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction And Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease.	<b>Phase 3</b>	<b>Sucampo</b>
2017-Present	<b>GS-US-419-3895/96</b> Combined Phase 2b/3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the	<b>Phase 3</b>	<b>Gilead</b>

	Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Ulcerative Colitis		
2017-2018	<b>GS-US-418-3898/99</b> A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active Moderate Crohn's Disease	<b>Phase 3</b>	<b>Gilead</b>
2017-2018	<b>RECD3125</b> A Multicenter, Double-Blind, Parallel-Arm, Placebo-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Orally Administered Full-Spectrum Microbiota™ (CPI01) in Subjects with Recurrence of <i>Clostridium difficile</i> Infection	<b>Phase 3</b>	<b>Salix</b>
2017-Present	<b>CDI-001</b> A Phase 2B Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose Ranging Study of Oral PF-06651600 and PF-06700841 As Induction and Chronic Therapy in Subjects with Moderate to Severe Ulcerative Colitis	<b>Phase 2</b>	<b>Crestovo</b>
2017-2018	<b>B7981005</b> Helicobacter pylori Sample Collection Protocol PRE-THERAPY Subjects	<b>Phase 2B</b>	<b>Pfizer</b>
2017-2018	<b>AOOI</b> Helicobacter pylori Sample Collection Protocol POST-THERAPY Subjects	<b>Phase 3</b>	<b>DiaSorin</b>
2017- 2020	<b>ZOOI</b> A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study to Evaluate the Efficacy, Safety, and Tolerability of a Clostridium Difficile Vaccine in Adults 50 Years of Age and Older	<b>Phase 3</b>	<b>DiaSorin</b>
2017- 2019	<b>B5091007</b> Calfe Sample Collection Study Protocol	<b>Phase 3</b>	<b>Pfizer</b>
2017-2018	<b>C-001</b> A prospective, multicenter, randomized, double-blind, Sham-controlled study to assess the efficacy and safety of the Vibrant capsule administered 5 times per week	<b>Phase 3</b>	<b>DiaSorin</b>
2017-2018	<b>240CLD</b> A prospective, multicenter, randomized, double-blind, Sham-controlled pilot study to assess the efficacy and safety of various vibrating capsule modes	<b>Phase 2</b>	<b>Vibrant Ltd</b>
2017- Present	<b>300CLD</b> A Phase 3 Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of SER-109 vs. Placebo to Reduce Recurrence of <i>Clostridium difficile</i> Infection (CDI) in Adults Who Have Received Antibacterial Drug Treatment for Recurrent CDI (RCDI)	<b>Phase 2</b>	<b>Vibrant Ltd</b>
2017- Present	<b>SERES-012</b> An Open-Label Extension of Study Seres-012 Evaluating SER-109 in Adult Subjects with Recurrent Clostridium Difficile Infection (RCDI)	<b>Phase 3</b>	<b>Seres Therapeutics</b>
2017- Present	<b>SERES-013</b> A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease	<b>Phase 3</b>	<b>Seres Therapeutics</b>
2018- Present	<b>CNT01275CRD3003</b> A Multicenter, Randomized, Double Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the studies M14-431 or M14-433	<b>Phase 3</b>	<b>Janssen</b>
2018- Present	<b>M14-430/M14-431/M14-433</b> A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment	<b>Phase 3</b>	<b>Abbvie</b>
	<b>M15-991/M16-006/M16-000</b>	<b>Phase 3</b>	<b>Abbvie</b>

2018- Present	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy <b>M16-067/M16-066</b>	<b>Phase 2b/3</b>	<b>Abbvie</b>
2018- Present	Efficacy and Safety of AbGn-168H in Patients with Moderate to Severe Active, Anti-TNF and/or Anti-Integrin Refractory Ulcerative Colitis: A 26-week, Open-Label, Multi-center, Phase II Proof of Principle Trial <b>2017.008.01</b>	<b>Phase 2</b>	<b>AbGenomics</b>
2018- Present	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease. <b>RPC01-3201</b>	<b>Phase 3</b>	<b>Celgene</b>
2018- Present	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease <b>RPC01-3203</b>	<b>Phase 3</b>	<b>Celgene</b>
2018- Present	A Phase 3, Multicenter, Open-Label Extension Study Of Oral Ozanimod For Moderately To Severely Active Crohn's Disease <b>RPC01-3204</b>	<b>Phase 3</b>	<b>Celgene</b>
2018- Present	A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Ulcerative Colitis <b>GS-US-418-4279</b>	<b>Phase 2</b>	<b>Gilead</b>
2018- Present	A Phase 3 Randomized, Open-Label (Sponsor-Blind), Active-Controlled, Parallel-Group, Multi-Center, Event Driven Study in Non-Dialysis Subjects with Anemia Associated with Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin alfa <b>200808</b>	<b>Phase 3</b>	<b>GSK</b>
2018- Present	Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in HLA-DQ2.5+ Adults with Celiac Disease To Assess the Effect of Nexvax2 on Symptoms After Masked Gluten Food Challenge <b>NexVax2-2006</b>	<b>Phase 2</b>	<b>ImmusanT</b>
2018-Present	A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients with Gastroesophageal Reflux Disease while receiving Proton Pump Inhibitors <b>C3718-301</b>	<b>Phase 3</b>	<b>Ironwood</b>
2018- Present	A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 µg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients with Irritable Bowel Syndrome with Constipation <b>MCP-103-312</b>	<b>Phase 3b</b>	<b>Ironwood</b>
2018- Present	A Phase 3b, Multicenter, Randomized, Blinded, Active Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Naïve Subjects with Moderately-to-Severely Active Crohn's Disease <b>CNTO1275CRD3007</b>	<b>Phase 3b</b>	<b>Janssen</b>
2018- Present	A prospective, Multicenter, Randomized, Single Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Vibrant Capsule vs. Vibrant Placebo for the Treatment of Chronic Idiopathic Constipation (CIC) <b>250CLD-01A</b>	<b>Phase 3</b>	<b>Vibrant Ltd</b>
2019-Present	Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 in Adult and Adolescent Subjects with Eosinophilic Esophagitis <b>SP-1011-003</b>	<b>Phase 3</b>	<b>Adare Pharmaceuticals, Inc.</b>
2019-Present	A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease <b>APD334-202</b>	<b>Phase 2/3</b>	<b>Arena</b>

2019-Present	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis <b>APD334-301</b>	<b>Phase 3</b>	<b>Pharmaceuticals, Inc.</b> <b>Arena Pharmaceuticals, Inc.</b>
2019-Present	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis <b>APD334-302</b>	<b>Phase 3</b>	<b>Arena Pharmaceuticals, Inc.</b>
2019-Present	An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis <b>APD334-303</b>	<b>Phase 3</b>	<b>Arena Pharmaceuticals, Inc.</b>
2019-Present	A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of Olorinab in Subjects with Irritable Bowel Syndrome Experiencing Abdominal Pain <b>APD371-202</b>	<b>Phase 2</b>	<b>Arena Pharmaceuticals, Inc.</b>
2019-Present	Clinical Validation of An Optimized Multi-Target Stool DNA (mt-sDNA 2.0) Test, for Colorectal Cancer Screening “BLUE-C” <b>2019-01</b>		<b>Exact Sciences</b>
2019-Present	Specimen Collection Study for Colorectal Cancer and Advanced Adenomas <b>FRNM-002</b>		<b>Freenome, Inc.</b>
2019-Present	Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode (ECLIPSE) <b>02-GI-002</b>		<b>Guardant Health, Inc.</b>
2019-Present	A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Larazotide for Relief of Persistent Symptoms in Patients with Celiac Disease on a Gluten Free Diet <b>CeD-LA-3001</b>	<b>Phase 3</b>	<b>9 Meters Biopharma, Inc</b>
2019-Present	A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Platform Study Evaluating the Efficacy and Safety of Interventions in Participants with Moderately to Severely Active Crohn’s Disease <b>PLATFORMPACRD200</b>	<b>Phase 2</b>	<b>Janssen Research &amp; Development, LLC</b>
2019-Present	A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS <b>R668-EE-1774</b>	<b>Phase 3</b>	<b>Regeneron Pharmaceuticals, Inc.</b>
2020-Present	A Safety and Efficacy Comparison of BLI4900 Bowel Preparation versus an FDA-approved Comparator in Adult Subjects prior to Colonoscopy <b>BLI4900-301</b>	<b>Phase 3</b>	<b>Braintree Laboratories, Inc.</b>
2020-Present	A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository Formulation Administered with the Sephure® Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum <b>CHS1221</b>	<b>Phase 3</b>	<b>Cristcot HCA LLC</b>
2020-Present	PREEMPT CRC: Prevention of Colorectal Cancer Through Multiomics Blood Testing <b>FRNM-004</b>		<b>Freenome, Inc.</b>

2020-Present

A Phase 2, randomized, double-blind, placebo-controlled, multi-center study to evaluate GB004 in adult subjects with mild-to-moderate active ulcerative colitis

**GB004-2101**

**Phase 2**

**GB004, Inc**